172 related articles for article (PubMed ID: 34013207)
1. Combined
D'Amore F; Grinberg F; Mauler J; Galldiks N; Blazhenets G; Farrher E; Filss C; Stoffels G; Mottaghy FM; Lohmann P; Shah NJ; Langen KJ
Neurooncol Adv; 2021; 3(1):vdab044. PubMed ID: 34013207
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI.
Werner JM; Stoffels G; Lichtenstein T; Borggrefe J; Lohmann P; Ceccon G; Shah NJ; Fink GR; Langen KJ; Kabbasch C; Galldiks N
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1889-1901. PubMed ID: 31203420
[TBL] [Abstract][Full Text] [Related]
3. Sequential implementation of DSC-MR perfusion and dynamic [
Steidl E; Langen KJ; Hmeidan SA; Polomac N; Filss CP; Galldiks N; Lohmann P; Keil F; Filipski K; Mottaghy FM; Shah NJ; Steinbach JP; Hattingen E; Maurer GD
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1956-1965. PubMed ID: 33241456
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study.
Bashir A; Brennum J; Broholm H; Law I
J Neurosurg; 2018 Apr; 130(2):451-464. PubMed ID: 29624154
[TBL] [Abstract][Full Text] [Related]
5. Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multimodal and integrative 18F-FET PET/fast-DKI approach.
Lohmeier J; Radbruch H; Brenner W; Hamm B; Hansen B; Tietze A; Makowski MR
Eur Radiol; 2024 Apr; 34(4):2487-2499. PubMed ID: 37672058
[TBL] [Abstract][Full Text] [Related]
6. Static FET PET radiomics for the differentiation of treatment-related changes from glioma progression.
Müller M; Winz O; Gutsche R; Leijenaar RTH; Kocher M; Lerche C; Filss CP; Stoffels G; Steidl E; Hattingen E; Steinbach JP; Maurer GD; Heinzel A; Galldiks N; Mottaghy FM; Langen KJ; Lohmann P
J Neurooncol; 2022 Sep; 159(3):519-529. PubMed ID: 35852737
[TBL] [Abstract][Full Text] [Related]
7. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
8. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
[TBL] [Abstract][Full Text] [Related]
10. Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.
Galldiks N; Stoffels G; Filss CP; Piroth MD; Sabel M; Ruge MI; Herzog H; Shah NJ; Fink GR; Coenen HH; Langen KJ
J Nucl Med; 2012 Sep; 53(9):1367-74. PubMed ID: 22872742
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma Recurrence Versus Radiotherapy Injury: Combined Model of Diffusion Kurtosis Imaging and 11C-MET Using PET/MRI May Increase Accuracy of Differentiation.
Dang H; Zhang J; Wang R; Liu J; Fu H; Lin M; Xu B
Clin Nucl Med; 2022 Jun; 47(6):e428-e436. PubMed ID: 35439178
[TBL] [Abstract][Full Text] [Related]
12.
Maurer GD; Brucker DP; Stoffels G; Filipski K; Filss CP; Mottaghy FM; Galldiks N; Steinbach JP; Hattingen E; Langen KJ
J Nucl Med; 2020 Apr; 61(4):505-511. PubMed ID: 31519802
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Dynamic O-(2-[
Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
[TBL] [Abstract][Full Text] [Related]
15. Glioma Recurrence Versus Radiation Necrosis: Single-Session Multiparametric Approach Using Simultaneous O-(2-18F-Fluoroethyl)-L-Tyrosine PET/MRI.
Jena A; Taneja S; Gambhir A; Mishra AK; Dʼsouza MM; Verma SM; Hazari PP; Negi P; Jhadav GK; Sogani SK
Clin Nucl Med; 2016 May; 41(5):e228-36. PubMed ID: 26859208
[TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET.
Kertels O; Mihovilovic MI; Linsenmann T; Kessler AF; Tran-Gia J; Kircher M; Brumberg J; Monoranu CM; Samnick S; Ernestus RI; Löhr M; Meyer PT; Lapa C
Clin Nucl Med; 2019 Sep; 44(9):695-701. PubMed ID: 31274552
[TBL] [Abstract][Full Text] [Related]
17. Potential for differentiation of glioma recurrence from radionecrosis using integrated
Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
[TBL] [Abstract][Full Text] [Related]
18. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
[TBL] [Abstract][Full Text] [Related]
19. Early Treatment Response Assessment Using
Ceccon G; Lohmann P; Werner JM; Tscherpel C; Dunkl V; Stoffels G; Rosen J; Rapp M; Sabel M; Herrlinger U; Schäfer N; Shah NJ; Fink GR; Langen KJ; Galldiks N
J Nucl Med; 2021 Jul; 62(7):918-925. PubMed ID: 33158907
[TBL] [Abstract][Full Text] [Related]
20. Suspected recurrence of brain metastases after focused high dose radiotherapy: can [
Romagna A; Unterrainer M; Schmid-Tannwald C; Brendel M; Tonn JC; Nachbichler SB; Muacevic A; Bartenstein P; Kreth FW; Albert NL
Radiat Oncol; 2016 Oct; 11(1):139. PubMed ID: 27769279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
